Kolltan Pharmaceuticals to Present at the 2015 American Association for Cancer Research (AACR) Annual Meeting

NEW HAVEN, Conn. – March 19, 2015 -- Kolltan Pharmaceuticals, Inc. today announced that the Company will present preclinical data from certain of its drug development programs at the American Association for Cancer Research (AACR) Annual Meeting, which will take place in Philadelphia, Pennsylvania, April 18-22, 2015.

Following are the specifics for five abstracts being presented at the AACR conference, including session times and authors:

- "Association of ErbB/HER biomarkers with antitumor activity of the anti-ErbB3/HER3 monoclonal antibody KTN3379 in SCCHN." Poster Session: Therapeutic Targeting of the Microenvironment, Abstract Number 1558, Monday, April 20, 2015, 8:00 AM -12:00 PM ET, Location: Section 20, Poster Board No. 27.

  Authors: Diego Alvarado, Jerry Wallweber, Scott Seibel, Ahmed Chenna, Roy Ravanera, Weidong Huang, David Stathas, Paul Theobald, Theresa M. LaVallee. Kolltan Pharmaceuticals; Monogram Biosciences/LabCorp, South San Francisco, CA.

- "Structural basis for inhibition of ligand-dependent and -independent ErbB3 activation by KTN3379." Poster Session: Growth Factor Receptors and Other Surface Antigens as Targets for Therapy, Abstract Number 1672, Monday, April 20, 2015, 8:00 AM -12:00 PM ET, Location: Section 29, Poster Board No. 5.


- "HER3 inhibition potentiates anti-tumor effects of PI3K inhibitors in pre-clinical models of HNSCC." Poster Session: Growth Factor Receptors and Other Surface Antigens as Targets for Therapy, Abstract Number 1674, Monday, April 20, 2015, 8:00 AM -12:00 PM ET, Location: Section 29, Poster Board No. 7.

  Authors: Kara S. Davis, Nayel Khan, Carolyn Kemp, Sucheta Kulkarni, Diego Alvarado, Theresa LaVallee, Jennifer R. Grandis, Umamaheswar Duvvuri. University of Pittsburgh Medical Center, Pittsburgh, PA; Kolltan Pharmaceuticals.

- "Blocking activity of a novel anti-MET humanized monoclonal antibody, KTN0216, is enhanced by IgG2 isotype in HGF-dependent and Met-amplified tumors." Poster Session: Growth Factor Receptors and Other Surface Antigens as Targets for Therapy, Abstract Number 1696, Monday, April 20, 2015, 8:00 AM -12:00 PM ET, Location: Section 29, Poster Board No. 29.

- "Dual ErbB blockade with KTN3379 and cetuximab yields enhanced antitumor activity by inhibiting parallel signaling pathways in SCCHN." Poster Session: Novel Mechanisms of Drug Pharmacology and Toxicity, Abstract Number 2615, Monday, April 20, 2015, 1:00 PM - 5:00 PM ET, Location: Section 30, Poster Board No. 7.

Authors: Diego Alvarado, Scott B. Seibel, Gwenda F. Ligon, Jay S. Lillquist, Andrew Pierce, Richard Gedrich, Theresa M. LaVallee. Kolltan Pharmaceuticals; MedImmune, Gaithersburg, MD.

About Kolltan Pharmaceuticals

Kolltan, a privately held clinical-stage company, is focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases for the treatment of cancer and other diseases with significant unmet need. Kolltan’s founders and members of its management team have deep expertise and a proven track record in drug discovery, development and commercialization of innovative therapeutics, including drugs targeting kinases. Kolltan is working in close collaboration with the laboratory of Kolltan Co-Founder, Dr. Joseph Schlessinger, as well as the Yale University medical and scientific community. The Company has a broad and novel portfolio of therapeutic biologics targeting multiple receptor tyrosine kinases that are advancing in clinical and preclinical development and are expected to generate multiple near-term milestones.

Contacts
Media Inquiries
Burns McClellan
Justin Jackson, 212-213-0006
jjackson@burnsmc.com
or
Investor Inquiries
Kolltan Pharmaceuticals, Inc.
203-907-0938

Source: Kolltan Pharmaceuticals